![](https://monteverdelaw.com/wp-content/uploads/case-logo/millendo-therapeutics-inc.png)
Millendo Therapeutics, Inc. (MLND) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company.
Millendo Therapeutics, Inc. (MLND) relating to its proposed merger with Tempest Therapeutics, Inc. Under the terms of the agreement, MLND shareholders are expected to own 18.5% of the combined company.